Skip to main content

Table 3 Changes of ALT (IU/L) over time assessed by linear mixed effects models for patients treated with TDF vs. untreated

From: Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study

  Crude model   Adjusted for baseline age, gender, ethnicity
  Coefficient β (95% CI) p-value Coefficient β (95% CI) p-value
(Intercept) 30.182 (26.944, 33.421) < 0.001 44.491 (35.438, 53.545) < 0.001
Group 23.566 (17.691, 29.440) < 0.001 21.868 (16.058, 27.677) < 0.001
Time −0.055 (− 0.169, 0.059) 0.346 − 0.055 (− 0.168, 0.059) 0.347
Group x Time a − 0.562 (− 0.752, − 0.372) < 0.001 −0.579 (− 0.768, − 0.390) < 0.001
  1. a x indicates the interaction between group and follow-up time. Group = {0,1}, where 0 indicates untreated, 1 indicates TDF. ALT Alanine aminotransferase; CI,confidence interval; TDF Tenofovir disoproxil fumarate